Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
The Percutaneous Transmural Arterial Bypass -1 Study (Post Approval Registry)
NCT06315023 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this post-market surveillance study will be to evaluate the real-world use of the DETOUR System in treated patients with symptomatic femoropopliteal lesions from 200 mm to 460 mm in length with chronic total occlusions (100 mm to 425 mm) or diffuse stenosis \> 70% who may be considered suboptimal candidates for surgical or alternative endovascular treatments.
Conditions Studied
Interventions
- DEVICE DETOUR System
Study Locations (10)
Pennsylvania
- University of Pennsylvania — West Chester
- Main Line Health — Wynnewood
California
- Salinas Valley Memorial Hospital — Salinas
Connecticut
- University of Connecticut — Storrs
District of Columbia
- Medstar Washington Hospital Center — Washington D.C.
Florida
- Delray Medical Center — Delray Beach
Massachusetts
- Beth Isreal Deaconess Medical Center — Boston
Missouri
- Saint Luke's Hospital of Kansas City — Kansas City
New York
- NYU Langone Medical Center — New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2023-10-06 |
| Est. Completion | 2032-06-07 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06315023
The ClinicalTrials.gov registry entry for NCT06315023 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endologix, which has 10 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 1 intervention — of which DETOUR System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06315023 reports 10 study locations spanning 9 distinct geographic areas — top geographies include Pennsylvania, California, Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06315023 about?
NCT06315023 is a clinical study titled "The Percutaneous Transmural Arterial Bypass -1 Study (Post Approval Registry)". The purpose of this post-market surveillance study will be to evaluate the real-world use of the DETOUR System in treated patients with symptomatic femoropopliteal lesions from 200 mm to 460 mm in length with chronic total occlusions (100 mm to 425 mm) or diffuse stenosis \> 70% who may be considere...
What is the current status of trial NCT06315023?
This trial is currently recruiting. The enrollment target is 450 participants. The study started on 2023-10-06. Estimated completion is 2032-06-07.
What conditions does trial NCT06315023 study?
This clinical trial studies the following conditions: Peripheral Arterial Disease, Symptomatic Femoropopliteal Lesions. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06315023?
The interventions under investigation include: DETOUR System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06315023?
This trial is sponsored by Endologix, which has 10 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06315023 being conducted?
This trial has 10 study locations across California, Connecticut, District of Columbia, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.